Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre

BACKGROUND: Study aimed to characterise treatment and outcomes for patients with hormone receptor positive (HR+), human epidermal growth factor 2 negative (HER2-) metastatic breast cancer (MBC) within a large regional cancer centre, as a benchmark for evaluating real-world impact of novel therapies....

Descripción completa

Detalles Bibliográficos
Autores principales: Twelves, Chris, Cheeseman, Sue, Sopwith, Will, Thompson, Matthew, Riaz, Majid, Ahat-Donker, Necibe, Myland, Melissa, Lee, Adam, Przybysz, Raymond, Turner, Stuart, Hall, Geoff, Perren, Tim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6975018/
https://www.ncbi.nlm.nih.gov/pubmed/31964373
http://dx.doi.org/10.1186/s12885-020-6527-y

Ejemplares similares

Ejemplares similares